Minu Dutia
Pfizer (United States)(US)
Publications by Year
Research Areas
Synthesis and biological activity, Protein Kinase Regulation and GTPase Signaling, Melanoma and MAPK Pathways, Quinazolinone synthesis and applications, Bioactive Compounds and Antitumor Agents
Most-Cited Works
- → Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent .beta.-adrenergic agonist virtually specific for .beta.3 receptors. A promising antidiabetic and antiobesity agent(1992)296 cited
- → Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity(2001)219 cited
- → Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles(2001)86 cited
- → Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines.(1994)81 cited
- → Novel Multidrug Resistance Reversal Agents(1999)66 cited
- → Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment(2008)42 cited
- → Potential antiatherosclerotic agents. 5. An acyl-coenzyme A:cholesterol O-acyltransferase inhibitor with hypocholesterolemic activity(1986)36 cited
- → Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors(2009)35 cited
- → Novel pyrazolopyrimidines as highly potent B-Raf inhibitors(2009)30 cited
- → Synthesis and evaluation of 4-Anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade(2003)28 cited